Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis

Expert Review of Clinical Pharmacology

Volumn 6, Issue 4, 2013, Pages 355-362

  Stangel, Martin ^a   Linker, Ralf A ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

dimethyl fumarate; fumaric acid; immune treatment; immunomodulation; multiple sclerosis

Indexed keywords

AMINOTRANSFERASE; BETA INTERFERON; EFALIZUMAB; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; NATALIZUMAB; PLACEBO; TRANSCRIPTION FACTOR NRF2;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; IMMUNOMODULATION; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING;

ANIMALS; FUMARATES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NF-E2-RELATED FACTOR 2; TREATMENT OUTCOME;

EID: 84883213453     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.811826     Document Type: Review

References (44)

1. Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221-1231 (2002).
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder Annu. Rev. Neurosci. 31, 247-269 (2008).
3. The IFNB Multiple Sclerosis Study Group. Interferon-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
4. Paty DW, Li DK. Interferon-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43(4), 662-667 (1993).
5. European Study Group on interferon-1b in secondary progressive MS. Placebocontrolled multicentre randomised trial of interferon-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497 (1998).
6. Goodin DS, Traboulsee A, Knappertz V et al.; 16-Year Long Term Follow-up Study Investigators. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon-1b trial in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 83(3), 282-287 (2012).
7. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268-1276 (1995).
8. Mikol DD, Barkhof F, Chang P et al.; REGARD study group. Comparison of subcutaneous interferon-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 7(10), 903-914 (2008).
9. Hartung HP, Gonsette R, König N et al.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial. Lancet 360(9350), 2018-2025 (2002).
10. Stroet A, Hemmelmann C, Starck M et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther. Adv. Neurol. Disord. 5(2), 75-79 (2012).
11. Polman CH, O'Connor PW, Havrdova E et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-910 (2006).
12. Clifford DB, De Luca A, DeLuca A et al. Natalizumab-Associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9(4), 438-446 (2010).
13. Bloomgren G, Richman S, Hotermans C et al. Risk of natalizumab-Associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366(20), 1870-1880 (2012).
14. Kappos L, Radue EW, O'Connor P et al.; FREEDOMS Study Group. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387-401 (2010).
15. Schweckendiek W. Treatment of psoriasis vulgaris. Med. Monatsschr. 13(2), 103-104 (1959).
16. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermatol. 30(6), 977-981 (1994).
17. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J. Am. Acad. Dermatol. 27(5 Pt 1), 769-771 (1992).
18. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol. 138(3), 456-460 (1998).
19. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin. Immunol. 142(1), 44-48 (2012).
20. Schimrigk S, Brune N, Hellwig K et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13(6), 604-610 (2006).
21. Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr. Opin. Investig. Drugs 8(11), 955-962 (2007).
22. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm. Drug Dispos. 24(6), 259-273 (2003).
23. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br. J. Dermatol. 141(3), 424-429 (1999).
24. Litjens NH, Burggraaf J, van Strijen E et al. Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol. 58(4), 429-432 (2004).
25. Altmeyer P, Hartwig R, Matthes U. Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt. 47(3), 190-196 (1996).
26. Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 121(6), 1383-1388 (2003).
27. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26(9), 2067-2074 (1996).
28. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116(2), 203-208 (2001).
29. Litjens NH, Rademaker M, Ravensbergen B et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 34(2), 565-575 (2004).
30. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol. Med. 11(1), 43-48 (2005).
31. Scannevin RH, Chollate S, Jung MY et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 341(1), 274-284 (2012).
32. Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678-692 (2011).
33. Moharregh-Khiabani D, Blank A, Skripuletz T et al. Effects of fumaric acids on cuprizone induced central nervous system de-And remyelination in the mouse. PLoS ONE 5(7), e11769 (2010).
34. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 234(1), 19-23 (1997).
35. Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxification enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 166(1-2), 132-143 (2005).
36. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1, TNF-And IL-6 in an in vitro model of brain inflammation. J. Neuroinflammation 7, 30 (2010).
37. Lin SX, Lisi L, Dello Russo C et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro. 3(2), e00055 (2011).
38. Kappos L, Gold R, Miller DH et al.; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372(9648), 1463-1472 (2008).
39. MacManus DG, Miller DH, Kappos L et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J. Neurol. 258(3), 449-456 (2011).
40. Gold R, Kappos L, Arnold DL et al.; DEFINE Study Investigators. Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367(12), 1098-1107 (2012).
41. Fox RJ, Miller DH, Phillips JT et al.; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367(12), 1087-1097 (2012).
42. Ermis U, Weis J, Schulz J. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368, 1657-1658 (2013).
43. Stoppe MG, Thomä E, Liebert UG, Claßen J, Then Bergh F. PML bei Psoriasis vulgaris nach Efalizumab und aktueller Therapie mit oralem Fumarat. Abstracts of the Meeting of the Deutsche Gesellschaft für Neurologie. (2012) (Abstract P616).
44. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimathyl fumarate from a compounding pharmacy. N.Engl.J.Med. 368(17), 1658-1659 (2013).